RxSightvsThermo Fisher Scientific

RXST and TMO stock compared: price, dividend, valuation and results, from SEC filings.

TMO

Thermo Fisher Scientific Inc

$700.22

Value $260B

+0.11%
TMO's page

RxSight (RXST) has a market value of $220M and Thermo Fisher Scientific (TMO) $260B. Over the last year, with dividends, RXST moved -46.9% and TMO +19.5%. Dividend yield: RXST none, TMO 0.26%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    RXST$220M

    TMO$260B

    TMO is 1,185 times RXST

  • Revenue, 12 months

    RXST$122M

    TMO$47.4B

    TMO is 389 times RXST

  • Net income, 12 months

    RXST-$53M

    TMO$7.1B

  • Operating margin

    RXST-50.4%

    TMO17.9%

    68.3 points apart

  • ROIC

    RXST-18.2%

    TMO8.2%

    26.3 points apart

  • P/E

    RXST–

    TMO36.8

  • Dividend yield

    RXST0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    RXST-56.7%

    TMO+11.8%

    68.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

RXST-56.7%

TMO+11.8%

20040020222023202420252026
Returns by period
PeriodRXSTWith dividendsTMOWith dividends
1 year since November 12, 2025-46.9%Price -46.9%+19.5%Price +19.1%
3 years since November 13, 2023-79.4%-41.0% a yearPrice -79.4%+58.8%+16.7% a yearPrice +57.3%
5 years since November 12, 2021-56.7%-15.4% a yearPrice -56.7%+11.8%+2.3% a yearPrice +10.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

RXSTRxSightTMOThermo Fisher Scientific

Valuation

RXSTTMO
Valuation
Price$5.32$700.22
Market value$220M$260B
Enterprise value (EV)–$295B
P/E–36.8
P/E, 5-year median–32.7
P/B0.94.8
EV/EBIT–34.9
Free cash flow yield8.5%2.9%

Results and growth

RXSTTMO
Results and growth
Revenue, 12 months$122M$47.4B
Net income, 12 months-$53M$7.1B
Free cash flow, 12 months$19M$7.6B
Earnings per share, 12 months-$1.28$18.96
Revenue growth, year on year-3.9%3.9%
Revenue growth a year, past+55.7%over 5 years+6.7%over 5 years
EPS growth a year, past–+2.1%over 5 years

Margins and returns on capital

RXSTTMO
Margins and returns on capital
Gross margin80.6%–
Operating margin-50.4%17.9%
Net margin-43.8%14.9%
ROIC-18.2%8.2%
ROE-20.0%13.4%

Balance sheet

RXSTTMO
Balance sheet
Cash$255M$6.1B
Total debt$10M$41.4B
Net debt / EBITDA–3.7
Interest cover-4,727.2×5.5×

Dividends and buybacks

RXSTTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: RXST or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, RxSight or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($260B) is about 1,184.9 times RxSight ($220M), at today's prices.

How did RXST and TMO stock do over the last 5 years?

Since November 12, 2021, RXST's price moved -56.7% and TMO's +10.2%. With dividends: RXST -56.7% (-15.4% a year), TMO +11.8% (+2.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, RXST or TMO?

The dividend yield at today's price is none for RxSight and 0.26% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, RxSight or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -43.8% for RxSight and 14.9% for Thermo Fisher Scientific, and the operating margin -50.4% and 17.9%. Revenue was $122M and $47.4B.

Which is the better investment, RxSight or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.